Join Novalix at Antifibrotic Drug Development Summit 2024 in Boston, MA, from November 19 to 21!
The 8th annual AFDD forum for cross-fibrosis disease insights will focus on the latest innovations from discovery and novel targets to preclininal models and early-stage clinical trials to accelerate antifibrotic therapy development.
Novalix scientists own a proven track record in assembling assay cascades and in vivo models for projects dealing with mutiple fibrotic disease indications. In each rodent model, an extensive panel of efficacy and biomarkers readouts is offered.
Come and discuss your needs with our team at our booth or during the poster presentation.
PCKD, the Most Relevant Model for ADPKD
Laurent Saniere, PhD, Senior Vice-President Pharmacology and DMPK, will present our scientific poster on November 20 from 5:15 p.m. at the Hilton Boston Back Bay, Maverick Room. Do not miss the session!
Abstract of the poster: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder, affecting 12 million people globally. It is characterized by the development of fluid-filled kidney cysts, which often leads to kidney failure. The vasopressin receptor 2 antagonist, Tolvaptan, is the only approved treatment that slows the progression of ADPKD. Nevertheless, there is still a high unmet need for treatment options for patients with ADPKD because Tolvaptan has limited efficacy and non-negligible side effects.
Click on the picture to discover our poster:
Join us at our booth
Contact our team to set up a meeting at our booth:
Anne Pecquery, Director Business Development Drug Discovery & Pharmacology
Laurent Saniere, PhD, Senior Vice-President Pharmacology & DMPK
Sonia D., PhD, Director Translational Science
